| MSM (n = 25) | Placebo (n = 25) |  | Significance for between group differences at follow-ups | |||||
---|---|---|---|---|---|---|---|---|---|
 | 6 weeks | 12 weeks | Difference 0-12 wk [CI] | 6 weeks | 12 weeks | Difference 0-12 wk [CI] | Between group difference [CI] | 0-6 wks | 0-12 wks |
WOMAC | Â | Â | Â | Â | Â | Â | Â | Â | Â |
   Pain | 35.5 ± 26.1 | 34.0 ± 24.5 | -9.0 ± 24.0 [-18.9, 0.9] | 47.1 ± 26.6 | 49.4 ± 20.8 | 3.5 ± 19.3 [-4.5, 11.5] | 12.4 [0.0, 24.8] | 0.20 | 0.05* |
   Stiffness | 39.2 ± 31.0 | 36.0 ± 26.2 | -11.7 ± 30.7 [-24.3, 1.0] | 52.9 ± 30.4 | 58.5 ± 24.2 | 15.5 ± 35.8 [0.7, 30.3] | 27.2 [8.2, 46.2] | 0.03* | 0.01* |
   Function | 36.6 ± 23.7 | 33.1 ± 23.1 | -7.7 ± 19.3 [-15.8, 0.3] | 46.2 ± 25.1 | 54.3 ± 21.1 | 6.9 ± 17.0 [0.1, 13.9] | 14.6 [4.3, 25.0] | 0.51 | 0.01* |
   Total | 36.6 ± 23.9 | 33.3 ± 22.5 | -8.4 ± 17.8 [-15.8, -1.1] | 47.2 ± 24.5 | 53.5 ± 20.3 | 6.5 ± 17.0 [0.5, 13.5] | 15.0 [5.1, 24.9] | 0.26 | 0.00* |
ALF | 36.5 ± 16.6 | 36.9 ± 20.7 | -6.8 ± 10.3 [-11.0, -2.5] | 32.2 ± 10.6 | 33.9 ± 10.9 | 0.8 ± 4.9 [-1.2, 2.8] | 7.6 [2.9, 12.2] | 0.02* | 0.00* |
SF-36 | 59.8 ± 19.7 | 62.2 ± 20.3 | 8.1 ± 21.8 [-0.8, 17.1] | 61.1 ± 16.2 | 54.5 ± 15.4 | -3.4 ± 14.6 [-9.5, 2.6] | -11.6 [-22.1, -1.0] | 0.52 | 0.03* |
VAS | 3.30 ± 2.8 | 3.61 ± 2.9 | -0.2 ± 3.2 [-1.5, 1.1] | 5.22 ± 2.9 | 5.16 ± 2.22 | 0.6 ± 2.7 [-0.6, 1.7] | 0.7 [-0.9, 2.4] | 0.18 | 0.38 |